The immune system's redesigned role in fighting cancerous tumors

March 12, 2014

Researchers in the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute eradicated solid tumors in laboratory mice using a novel combination of two targeted agents. These two synergistic therapies stimulate an immune response, ultimately allowing solid tumors to act as their own cancer-fighting vaccine.

The study's findings, published in the journal Cancer Research, are the first to use these combined agents as an immune stimulator and may have the potential to kill cancerous cells in solid tumors, including some of the most aggressive cancers that form in the lung and pancreas. Investigators hope to bring this science to early-phase clinical trials in coming months.

"Instead of administering a cancer vaccine to destroy tumors, we hope to modify the immune system to allow the patient's own tumor to act as a cancer vaccine," said Hyung Lae Kim, MD, co-medical director of the Urologic Oncology Program and lead author of the study. "This approach differs from traditional methods, where the immune system is stimulated by administering a vaccine. Instead, we administer a combination therapy to allow , which are capable of killing tumors, to see tumors that were previously invisible to the immune system."

When an immune system is working properly, diseased cells are captured and killed. However, are formed when the immune system is unable to remove these . Using an "mTOR inhibitor," which regulates cellular metabolism, and a CD4 antibody, which helps to initiate an , researchers increased the immune system's "memory" and ability to recognize and fight off tumors.

"With our approach, investigators simply combine an mTOR inhibitor and CD4 antibody to create an immunotherapy treatment, requiring no surgery and a drug with virtually no shelf life," said Robert Figlin, MD, deputy director of the Samuel Oschin Comprehensive Cancer Institute and the Steven Spielberg Family Chair in Hematology-Oncology. "This broad implication is in contrast to a more traditional vaccine-based approach, which requires a specialist to surgically remove tumor samples from a patient's body then create a personalized vaccine approach for one specific patient."

The combination of a CD4 antibody with an mTOR inhibitor may enhance and eradicate . Additional research is being done to better understand how the drugs work and develop optimal strategies for applications in patients.

Explore further: Kidney cancer care improves with vaccine-based approach

More information: Citation: Cancer Research. 2014 February: Foxp3+ T cells inhibit antitumor immune memory modulated by mTOR inhibition.

Related Stories

Kidney cancer care improves with vaccine-based approach

February 19, 2014
The Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute has opened a novel Phase III, vaccine-based clinical trial aimed at providing kidney cancer patients long-term control of their disease.

Novel cancer vaccine holds promise against ovarian cancer, mesothelioma

March 5, 2014
A novel approach to cancer immunotherapy – strategies designed to induce the immune system to attack cancer cells – may provide a new and cost-effective weapon against some of the most deadly tumors, including ovarian ...

Cancer vaccine could use immune system to fight tumors

February 27, 2014
Cincinnati Cancer Center (CCC) and UC Cancer Institute researchers have found that a vaccine, targeting tumors that produce a certain protein and receptor responsible for communication between cells and the body's immune ...

Researchers target cancer stem cells in malignant brain tumors

January 6, 2014
Researchers at the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Department of Neurosurgery identified immune system targets on cancer stem cells – cells from which malignant brain tumors are believed to originate ...

Infecting just one tumor with a virus could boost the systemic effectiveness of cancer immunotherapy

March 5, 2014
A Ludwig Cancer Research study suggests that the clinical efficacy of checkpoint blockade, a powerful new strategy to harness the immune response to treat cancers, might be dramatically improved if combined with oncolytic ...

Researchers find promising results with local hyperthermia of tumors

March 4, 2014
A combination of iron-oxide nanoparticles and an alternating magnetic field, which together generate heat, have activated an immune system response to tumors in mice according to an accepted manuscript by Dartmouth-Hitchcock ...

Recommended for you

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.